Ontario Teachers Pension Plan Board increased its position in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) by 346.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 49,627 shares of the company’s stock after purchasing an additional 38,505 shares during the period. Ontario Teachers Pension Plan Board’s holdings in Progyny were worth $856,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in PGNY. GAMMA Investing LLC increased its holdings in shares of Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after acquiring an additional 1,246 shares in the last quarter. Signaturefd LLC increased its stake in Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after purchasing an additional 1,355 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after buying an additional 1,526 shares during the last quarter. KBC Group NV raised its holdings in Progyny by 84.6% during the fourth quarter. KBC Group NV now owns 4,669 shares of the company’s stock worth $81,000 after buying an additional 2,140 shares during the last quarter. Finally, F M Investments LLC lifted its stake in shares of Progyny by 13.0% in the fourth quarter. F M Investments LLC now owns 20,420 shares of the company’s stock valued at $352,000 after buying an additional 2,342 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.
Wall Street Analyst Weigh In
PGNY has been the topic of a number of analyst reports. Bank of America upped their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Canaccord Genuity Group increased their price objective on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, February 28th. BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price on the stock in a research report on Monday, March 31st. Finally, JPMorgan Chase & Co. increased their price target on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Progyny currently has a consensus rating of “Hold” and an average price target of $23.64.
Progyny Stock Performance
Shares of NASDAQ:PGNY opened at $21.40 on Thursday. The company has a market capitalization of $1.83 billion, a P/E ratio of 36.90, a price-to-earnings-growth ratio of 2.39 and a beta of 1.33. The company’s 50-day moving average is $21.98 and its 200 day moving average is $18.77. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $33.84.
About Progyny
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Featured Articles
- Five stocks we like better than Progyny
- Quiet Period Expirations Explained
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- Stock Market Sectors: What Are They and How Many Are There?
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.